Primary pulmonary hypertension: A vascular biology and translational research 'work in progress'

Circulation

Volumn 102, Issue 22, 2000, Pages 2781-2791

  Archer, S ^a   Rich, S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Endothelin; Hypertension, pulmonary; Ion channels; Nitric oxide; Platelets; Potassium

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL; PROSTACYCLIN; VASODILATOR AGENT; WARFARIN;

ARTICLE; CHROMOSOME 2; DYSPNEA; HEART DEPOLARIZATION; HEART VENTRICLE OVERLOAD; LUNG VASCULAR RESISTANCE; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYNCOPE; THORAX PAIN; VASCULAR ENDOTHELIUM;

EID: 0034727717     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.22.2781     Document Type: Article

References (108)

1. Ueber slerose der lungenarterien
2. Uber die genuine arteriosklerose der lungenarterie
3. Primary pulmonary hypertension. 1: Clinical and hemodynamic study
4. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension
5. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension
6. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
7. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth
8. Primary pulmonary hypertension between inflammation and cancer
9. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
10. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32
11. Hormone replacement therapy: A possible risk factor in carriers of familial primary pulmonary hypertension
12. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension
13. The presence of genetic anticipation suggests that the molecular basis of familial primary pulmonary hypertension may be trinucleotide repeat expansion
14. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32
15. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease
16. Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome
17. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33
18. Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex
19. Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome
20. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension
21. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension
22. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension
23. Increased plasma serotonin in primary pulmonary hypertension
24. Endothelin-1 and serotonin: Mediators of primary and secondary pulmonary hypertension?
25. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin
26. Platelet membrane defects in fawn hooded bleeder rats
27. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat
28. Abnormal lung growth and the development of pulmonary hypertension in the fawn-hooded rat
29. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
30. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
31. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension
32. Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls
33. Urinary cGMP concentrations in severe primary pulmonary hypertension
34. Endothelin-1 is elevated in monocrotaline pulmonary hypertension
35. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension
36. Endothelin-1 in the lungs of patients with pulmonary hypertension
37. Plasma immunoreactive endothelin-1 concentrations in infants with persistent pulmonary hypertension of the newborn
38. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair
39. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension: Association with acute hypoxic pulmonary vasoreactivity
40. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation
41. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
42. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
43. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
44. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats
45. The mechanism of acute hypoxic pulmonary vasoconstriction: The tale of two channels
46. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction
47. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes
48. Attenuated K+ channel gene transcription in primary pulmonary hypertension
49. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes
50. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group
51. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension
52. It all begins with EVE (endogenous vascular elastase)
53. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2
54. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor
55. Pulmonary hypertension, 'plexogenic pulmonary artericopathy' and the appetite depressant drug aminorex: Post or propter
56. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
57. The anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction
58. Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells
59. Dexfenfluramine increases pulmonary artery smooth muscle intracellular Ca2+, independent of membrane potential
60. Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells
61. The toxic oil syndrome
62. Factors associated with pathogenicity of oils related to the toxic oil syndrome epidemic in Spain
63. The acute pathology of fatty acid anilides and linoleic diester of 3-phenylamino-1,2-propanediol in mice: Possible implication as aetiologic agents for the toxic oil syndrome
64. Acute effect of intrapulmonary enalaprilat in ten patients with severe pulmonary hypertension due to toxic oil syndrome
65. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome
66. Primary pulmonary hypertension associated with human immunodeficiency virus infection
67. Human immunodeficiency virus infection and pulmonary hypertension: Two new cases and a review of 86 reported cases
68. HIV-1 gp160 decreases the K+ voltage-gated current from Jurkat E6.1 T cells by up-phosphorylation
69. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide
70. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
71. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome
72. Signaling pathways for cardiac hypertrophy and failure
73. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients
74. Pulmonary hypertension and fenfluramine
75. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine
76. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
77. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels
78. The effect of high doscs of calcium-channel blockers on survival in primary pulmonary hypertension
79. Prostacyclin, from discovery to clinical application
80. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
81. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
82. Long-term effects of cicletanine on secondary pulmonary hypertension
83. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
84. Development of non-specific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin
85. Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension
86. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
87. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH study group
88. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
89. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn: Clinical Inhaled Nitric Oxide Research Group
90. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension
91. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
92. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats
93. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension
94. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: Effect on agonist-induced and flow-mediated vascular responses
95. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse
96. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary pulmonary Hypertension Study Group
97. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension
98. Thromboxane inhibition and monocrotaline-induced pulmonary hypertension in rats
99. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: Role of thromboxane A2
100. Prevention of complement-induced pulmonary hypertension and improvement of right ventricular function by selective thromboxane receptor antagonism
101. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist
102. Effects of vasoactive drugs on thromboxane A2 mimetic-induced pulmonary hypertension in newborn lambs
103. Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep
104. Thromboxane A2 mediates pulmonary hypertension after cardiopulmonary bypass in the rabbit
105. Bacterial lipopolysaccharide induction of the prostaglandin G/H synthase 2 gene causes thromboxane-dependent pulmonary hypertension in rabbits